Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
The U.S. Food and Drug Administration has approved Onureg, an oral formulation of the chemotherapy azacitidine, as a maintenance treatment for adults with newly diagnosed acute myeloid leukemia (AML) who ... Read more
Biosight‘s BST-236 (aspacytarabine), a less toxic form of chemotherapy for acute myeloid leukemia (AML), has received fast track designation from the U.S. Food and Drug Administration (FDA) for patients ages 75 ... Read more
The Phase 3 trial testing Rafael Pharmaceuticals‘ CPI-613 (devimistat) as a treatment for relapsed or refractory acute myeloid leukemia (AML) has enrolled more than half of the participants needed for ... Read more
Following discussions with the U.S. Food and Drug Administration (FDA), MacroGenics is planning for a single-arm clinical trial that supports the approval of its investigational molecule flotetuzumab for the treatment ... Read more
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Ryvu Therapeutics’ oral inhibitor SEL120 for treating people with acute myeloid leukemia (AML). In the U.S., orphan ... Read more
Treatment with MacroGenics‘ investigational molecule flotetuzumab completely eliminated traces of cancer cells in a large proportion of heavily treated acute myeloid leukemia (AML) patients, data from a Phase 1/2 clinical ... Read more
People with acute myeloid leukemia (AML) who are in complete remission after their first-line chemotherapy and not suitable for a stem cell transplant have significantly better survival outcomes if offered ... Read more